Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.

Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F (2015) Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol 21(23), 7281-7288. PubMed Open Access PDF

Abstract

To confirm the efficacy and safety of bevacizumab/XELOX combination for the treatment of locally advanced or metastatic colorectal cancer (CRC) in Italy.

HKI-Autoren
Identifier

doi: 10.3748/wjg.v21.i23.7281 PMID: 26109816